Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

Charles River Laboratories International, Inc. (CRL) EV/Assets Ratio: 1.56x

Is Charles River Laboratories International, Inc.’s EV/Assets ratio high or low?

Charles River Laboratories International, Inc.'s EV/Assets ratio of 1.56x is 20% below its 5-year average of 1.95x, near the low end of its 5-year range (1.01x–3.95x).

The EV/Assets ratio for Charles River Laboratories International, Inc. (CRL) is 1.56x as of Wednesday, June 10, 2026. It is above its 12-month average by 3.72% (1.50x).

CRL EV/Assets Ratio Chart

CRL EV/Assets Ratio
1.56x+13.04% 1Y
Zoom

CRL Average EV/Assets Ratio Chart

CRL Current vs Average EV/Assets Ratio Chart

CRL EV/Assets Ratio Metrics

EV/ASSETS RATIO

1.56x

EV/ASSETS RATIO AVG TTM

1.50x

EV/ASSETS RATIO AVG 3Y

1.60x

EV/ASSETS RATIO AVG 5Y

1.95x

EV/ASSETS RATIO AVG 10Y

2.07x

EV/ASSETS RATIO AVG 15Y

1.98x

EV/ASSETS RATIO AVG 20Y

1.82x

CURRENT VS TTM AVG

+3.72%

CURRENT VS 3Y AVG

-2.26%

CURRENT VS 5Y AVG

-20.07%

CURRENT VS 10Y AVG

-24.57%

CURRENT VS 15Y AVG

-21.33%

CURRENT VS 20Y AVG

-14.25%

CRL Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Charles River Laboratories International, Inc. (CRL)1.56x1.50x1.60x1.95x
Bio-Rad Laboratories, Inc. (BIO)$7.89B0.89x0.88x0.89x0.99x
Hims & Hers Health, Inc. (HIMS)$6.42B3.30x5.99x7.32x5.78x
Align Technology, Inc. (ALGN)$12.56B1.84x1.76x2.56x3.77x
Hologic, Inc. (HOLX)$16.97B1.91x1.84x1.98x2.08x
Moderna, Inc. (MRNA)$18.40B1.55x1.14x1.48x2.53x
BioNTech SE (BNTX)$21.81B0.44x0.55x0.54x1.39x
Mettler-Toledo International Inc. (MTD)$22.85B6.85x8.27x8.63x9.33x
Waters Corporation (WAT)$23.83B1.43x4.12x4.55x5.47x
Veeva Systems Inc. (VEEV)$27.37B2.85x4.64x5.33x7.00x

Charles River Laboratories International, Inc. EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Charles River Laboratories International, Inc. EV/Assets Ratio FAQ

What is the EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
The EV/Assets ratio for CRL stock is 1.56x.
Is Charles River Laboratories International, Inc.'s EV/Assets ratio high or low?
Charles River Laboratories International, Inc.'s EV/Assets ratio of 1.56x is 20% below its 5-year average of 1.95x, near the low end of its 5-year range (1.01x–3.95x).
What is the TTM average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
The TTM average EV/Assets ratio for CRL stock is 1.50x.
What is the 3Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
The 3Y average EV/Assets ratio for CRL stock is 1.60x.
What is the 5Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
The 5Y average EV/Assets ratio for CRL stock is 1.95x.
What is the 10Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
The 10Y average EV/Assets ratio for CRL stock is 2.07x.
What is the 15Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
The 15Y average EV/Assets ratio for CRL stock is 1.98x.
What is the 20Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
The 20Y average EV/Assets ratio for CRL stock is 1.82x.

Charles River Laboratories International, Inc. EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-101.56x
2026-06-091.57x
2026-06-081.55x
2026-06-051.52x
2026-06-041.55x
2026-06-031.51x
2026-06-021.48x
2026-06-011.52x
2026-05-291.51x
2026-05-281.52x
2026-05-271.41x
2026-05-261.36x
2026-05-221.39x
2026-05-211.38x
2026-05-201.36x
2026-05-191.34x
2026-05-181.32x
2026-05-151.33x
2026-05-141.38x
2026-05-131.40x
2026-05-121.44x
2026-05-111.44x
2026-05-081.50x
2026-05-071.52x
2026-05-061.65x
2026-05-051.68x
2026-05-041.59x
2026-05-011.54x
2026-04-301.55x
2026-04-291.53x
2026-04-281.55x
2026-04-271.58x
2026-04-241.57x
2026-04-231.56x
2026-04-221.67x
2026-04-211.66x
2026-04-201.68x
2026-04-171.67x
2026-04-161.62x
2026-04-151.65x
2026-04-141.64x
2026-04-131.63x
2026-04-101.61x
2026-04-091.61x
2026-04-081.61x
2026-04-071.57x
2026-04-061.56x
2026-04-021.60x
2026-04-011.61x
2026-03-311.59x
2026-03-301.50x
2026-03-271.50x
2026-03-261.54x
2026-03-251.54x
2026-03-241.50x
2026-03-231.49x
2026-03-201.46x
2026-03-191.46x
2026-03-181.48x
2026-03-171.46x
2026-03-161.45x
2026-03-131.47x
2026-03-121.45x
2026-03-111.56x
2026-03-101.55x
2026-03-091.62x
2026-03-061.60x
2026-03-051.65x
2026-03-041.64x
2026-03-031.61x
2026-03-021.63x
2026-02-271.63x
2026-02-261.61x
2026-02-251.56x
2026-02-241.55x
2026-02-231.53x
2026-02-201.56x
2026-02-191.53x
2026-02-181.49x
2026-02-171.37x
2026-02-131.38x
2026-02-121.37x
2026-02-111.41x
2026-02-101.51x
2026-02-091.54x
2026-02-061.57x
2026-02-051.53x
2026-02-041.65x
2026-02-031.65x
2026-02-021.73x
2026-01-301.71x
2026-01-291.71x
2026-01-281.75x
2026-01-271.77x
2026-01-261.79x
2026-01-231.77x
2026-01-221.80x
2026-01-211.81x
2026-01-201.76x
2026-01-161.77x
2026-01-151.79x
2026-01-141.75x
2026-01-131.76x
2026-01-121.76x
2026-01-091.78x
2026-01-081.74x
2026-01-071.75x
2026-01-061.74x
2026-01-051.69x
2026-01-021.65x
2025-12-311.63x
2025-12-301.65x
2025-12-291.66x
2025-12-261.66x
2025-12-241.66x
2025-12-231.66x
2025-12-221.66x
2025-12-191.62x
2025-12-181.60x
2025-12-171.61x
2025-12-161.61x
2025-12-151.63x
2025-12-121.59x
2025-12-111.60x
2025-12-101.60x
2025-12-091.55x
2025-12-081.55x
2025-12-051.53x
2025-12-041.53x
2025-12-031.54x
2025-12-021.47x
2025-12-011.48x
2025-11-281.49x
2025-11-261.50x
2025-11-251.49x
2025-11-241.44x
2025-11-211.43x
2025-11-201.39x
2025-11-191.39x
2025-11-181.39x
2025-11-171.39x
2025-11-141.43x
2025-11-131.44x
2025-11-121.45x
2025-11-111.46x
2025-11-101.43x
2025-11-071.43x
2025-11-061.45x
2025-11-051.43x
2025-11-041.50x
2025-11-031.51x
2025-10-311.52x
2025-10-301.51x
2025-10-291.52x
2025-10-281.57x
2025-10-271.62x
2025-10-241.63x
2025-10-231.59x
2025-10-221.56x
2025-10-211.57x
2025-10-201.55x
2025-10-171.51x
2025-10-161.49x
2025-10-151.46x
2025-10-141.45x
2025-10-131.46x
2025-10-101.43x
2025-10-091.47x
2025-10-081.48x
2025-10-071.45x
2025-10-061.49x
2025-10-031.50x
2025-10-021.49x
2025-10-011.46x
2025-09-301.36x
2025-09-291.30x
2025-09-261.31x
2025-09-251.29x
2025-09-241.32x
2025-09-231.32x
2025-09-221.35x
2025-09-191.36x
2025-09-181.37x
2025-09-171.34x
2025-09-161.33x
2025-09-151.34x
2025-09-121.34x
2025-09-111.39x
2025-09-101.34x
2025-09-091.37x
2025-09-081.40x
2025-09-051.41x
2025-09-041.40x
2025-09-031.40x
2025-09-021.40x
2025-08-291.41x
2025-08-281.41x
2025-08-271.41x
2025-08-261.41x
2025-08-251.41x
2025-08-221.40x
2025-08-211.35x
2025-08-201.39x
2025-08-191.38x
2025-08-181.37x
2025-08-151.37x
2025-08-141.36x
2025-08-131.36x
2025-08-121.34x
2025-08-111.32x
2025-08-081.31x
2025-08-071.32x
2025-08-061.32x
2025-08-051.49x
2025-08-041.49x
2025-08-011.48x
2025-07-311.50x
2025-07-301.55x
2025-07-291.56x
2025-07-281.56x
2025-07-251.55x
2025-07-241.55x
2025-07-231.49x
2025-07-221.46x
2025-07-211.37x
2025-07-181.40x
2025-07-171.41x
2025-07-161.40x
2025-07-151.40x
2025-07-141.42x
2025-07-111.43x
2025-07-101.46x
2025-07-091.43x
2025-07-081.43x
2025-07-071.40x
2025-07-031.42x
2025-07-021.42x
2025-07-011.40x
2025-06-301.38x
2025-06-271.37x
2025-06-261.38x
2025-06-251.37x
2025-06-241.36x
2025-06-231.35x
2025-06-201.35x
2025-06-181.34x
2025-06-171.34x
2025-06-161.38x
2025-06-131.37x
2025-06-121.38x
2025-06-111.38x
2025-06-101.38x
2025-06-091.35x
2025-06-061.33x
2025-06-051.31x
2025-06-041.32x
2025-06-031.29x
2025-06-021.27x
2025-05-301.27x
2025-05-291.29x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster